Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework.

Next Generation Sequencing clinical genomics genetic testing hereditary cancer laboratory automation

Journal

Diagnosis (Berlin, Germany)
ISSN: 2194-802X
Titre abrégé: Diagnosis (Berl)
Pays: Germany
ID NLM: 101654734

Informations de publication

Date de publication:
16 06 2021
Historique:
received: 09 04 2021
accepted: 12 05 2021
pubmed: 19 6 2021
medline: 6 5 2022
entrez: 18 6 2021
Statut: epublish

Résumé

The Next Generation Sequencing (NGS) based mutational study of hereditary cancer genes is crucial to design tailored prevention strategies in subjects with different hereditary cancer risk. The ease of amplicon-based NGS library construction protocols contrasts with the greater uniformity of enrichment provided by capture-based protocols and so with greater chances for detecting larger genomic rearrangements and copy-number variations. Capture-based protocols, however, are characterized by a higher level of complexity of sample handling, extremely susceptible to human bias. Robotics platforms may definitely help dealing with these limits, reducing hands-on time, limiting random errors and guaranteeing process standardization. We implemented the automation of the CE-IVD SOPHiA Hereditary Cancer Solution™ (HCS) libraries preparation workflow by SOPHiA GENETICS on the Hamilton's STARlet platform. We present the comparison of results between this automated approach, used for more than 1,000 DNA patients' samples, and the performances of the manual protocol evaluated by SOPHiA GENETICS onto 240 samples summarized in their HCS evaluation study. We demonstrate that this automated workflow achieved the same expected goals of manual setup in terms of coverages and reads uniformity, with extremely lower standard deviations among samples considering the sequencing reads mapped onto the regions of interest. This automated solution offers same reliable and affordable NGS data, but with the essential advantages of a flexible, automated and integrated framework, minimizing possible human errors and depicting a laboratory's walk-away scenario.

Identifiants

pubmed: 34142509
pii: dx-2021-0051
doi: 10.1515/dx-2021-0051
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115-122

Informations de copyright

© 2021 Walter de Gruyter GmbH, Berlin/Boston.

Références

Morganti, S, Tarantino, P, Ferraro, E, D’Amico, P, Viale, G, Trapani, D, et al.. Complexity of genome sequencing and reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol 2019;133:171–82. https://doi.org/10.1016/j.critrevonc.2018.11.008.
Giani, AM, Gallo, GR, Gianfranceschi, L, Formenti, G. Long walk to genomics: history and current approaches to genome sequencing and assembly. Comput Struct Biotechnol J 2020;18:9–19. https://doi.org/10.1016/j.csbj.2019.11.002.
Petersen, BS, Fredrich, B, Hoeppner, MP, Ellinghaus, D, Franke, A. Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet 2017;18:14. https://doi.org/10.1186/s12863-017-0479-5.
Arboleda, VA, Xian, RR. An overview of DNA analytical methods. Methods Mol Biol 2019;1897:385–402. https://doi.org/10.1007/978-1-4939-8935-5_31.
Xu, J, Yang, P, Xue, S, Sharma, B, Sanchez-Martin, M, Wang, F, et al.. Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. Hum Genet 2019;138:109–24. https://doi.org/10.1007/s00439-019-01970-5.
Ellingford, JM, Campbell, C, Barton, S, Bhaskar, S, Gupta, S, Taylor, RL, et al.. Validation of copy number variation analysis for next-generation sequencing diagnostics. Eur J Hum Genet 2017;25:719–24. https://doi.org/10.1038/ejhg.2017.42.
Tagliafico, E, Bernardis, I, Grasso, M, D’Apice, MR, Lapucci, C, Botta, A, et al.. Workload measurement for molecular genetics laboratory: a survey study. PloS One 2018;13:e0206855. https://doi.org/10.1371/journal.pone.0206855.
Katsanis, SH, Katsanis, N. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet 2013;14:415–26. https://doi.org/10.1038/nrg3493.
Greaves, RF, Bernardini, S, Ferrari, M, Fortina, P, Gouget, B, Gruson, D, et al.. Key questions about the future of laboratory medicine in the next decade of the 21st century: a report from the IFCC-Emerging Technologies Division. Clin Chim Acta 2019;495:570–89. https://doi.org/10.1016/j.cca.2019.05.021.
Neben, CL, Zimmer, AD, Stedden, W, van den Akker, J, O’Connor, R, Chan, RC, et al.. Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines. J Mol Diagn 2019;21:646–57. https://doi.org/10.1016/j.jmoldx.2019.03.001.
Susswein, LR, Marshall, ML, Nusbaum, R, Vogel Postula, KJ, Weissman, SM, Yackowski, L, et al.. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 2016;18:823–32. https://doi.org/10.1038/gim.2015.166.
Crawford, B, Adams, SB, Sittler, T, van den Akker, J, Chan, S, Leitner, O, et al.. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients. Breast Canc Res Treat 2017;163:383–90. https://doi.org/10.1007/s10549-017-4181-0.
Stern, B, McGarrity, T, Baker, M. Incorporating colorectal cancer genetic risk assessment into gastroenterology practice. Curr Treat Options Gastroenterol 2019;17:702–15. https://doi.org/10.1007/s11938-019-00267-w.
Cohen, SA, Pritchard, CC, Jarvik, GP. Lynch syndrome: from screening to diagnosis to treatment in the era of modern molecular oncology. Annu Rev Genom Hum Genet 2019;20:293–307. https://doi.org/10.1146/annurev-genom-083118-015406.
Kozarewa, I, Armisen, J, Gardner, AF, Slatko, BE, Hendrickson, CL. Overview of target enrichment strategies. Curr Protoc Mol Biol 2015;112:7.21.1–23. https://doi.org/10.1002/0471142727.mb0721s112.
Samorodnitsky, E, Jewell, BM, Hagopian, R, Miya, J, Wing, MR, Lyon, E, et al.. Evaluation of hybridization capture versus amplicon-based methods for whole-exome sequencing. Hum Mutat 2015;36:903–14. https://doi.org/10.1002/humu.22825.
Muscarella, LA, Fabrizio, FP, De Bonis, M, Mancini, MT, Balsamo, T, Graziano, P, et al.. Automated workflow for somatic and germline next generation sequencing analysis in routine clinical cancer diagnostics. Cancers 2019;11:1691. https://doi.org/10.3390/cancers11111691.
Wang, K, Li, M, Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164. https://doi.org/10.1093/nar/gkq603.
McLaren, W, Gil, L, Hunt, SE, Riat, HS, Ritchie, GR, Thormann, A, et al.. The ensembl variant effect predictor. Genome Biol 2016;17:122. https://doi.org/10.1186/s13059-016-0974-4.
Richards, S, Aziz, N, Bale, S, Bick, D, Das, S, Gastier-Foster, J, et al.. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24. https://doi.org/10.1038/gim.2015.30.
Mu, W, Lu, HM, Chen, J, Li, S, Elliott, AM. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn 2016;18:923–32. https://doi.org/10.1016/j.jmoldx.2016.07.006.
Hess, JF, Kohl, TA, Kotrova, M, Ronsch, K, Paprotka, T, Mohr, V, et al.. Library preparation for next generation sequencing: a review of automation strategies. Biotechnol Adv 2020;41:107537. https://doi.org/10.1016/j.biotechadv.2020.107537.
Quail, MA, Smith, M, Coupland, P, Otto, TD, Harris, SR, Connor, TR, et al.. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genom 2012;13:341. https://doi.org/10.1186/1471-2164-13-341.
Plebani, M. Harmonization in laboratory medicine: more than clinical chemistry? Clin Chem Lab Med 2018;56:1579–86. https://doi.org/10.1515/cclm-2017-0865.

Auteurs

Elena Tenedini (E)

Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics Unit, Modena University Hospital, Modena, Italy.
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Fabio Celestini (F)

Hamilton Italia S.r.l., Agrate Brianza (MB), Italy.

Pierluigi Iapicca (P)

SOPHiA GENETICS SA HQ, Saint-Sulpice, Switzerland.

Marco Marino (M)

Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics Unit, Modena University Hospital, Modena, Italy.

Sara Castellano (S)

Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
PhD Program in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, Italy.

Lucia Artuso (L)

Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics Unit, Modena University Hospital, Modena, Italy.

Fiammetta Biagiarelli (F)

SOPHiA GENETICS SA HQ, Saint-Sulpice, Switzerland.

Laura Cortesi (L)

Department of Oncology and Hematology, Modena University Hospital, Modena, Italy.

Angela Toss (A)

Department of Oncology and Hematology, Modena University Hospital, Modena, Italy.
Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, University of Modena and Reggio Emilia, Modena, Italy.

Elena Barbieri (E)

Department of Oncology and Hematology, Modena University Hospital, Modena, Italy.

Luca Roncucci (L)

Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Monica Pedroni (M)

Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Rossella Manfredini (R)

Life Sciences Department, University of Modena and Reggio Emilia, Centre for Regenerative Medicine, Modena, Italy.

Mario Luppi (M)

Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Department of Oncology and Hematology, Modena University Hospital, Modena, Italy.

Tommaso Trenti (T)

Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics Unit, Modena University Hospital, Modena, Italy.

Enrico Tagliafico (E)

Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics Unit, Modena University Hospital, Modena, Italy.
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH